GC
JAZZ icon

Gratry & Company’s Jazz Pharmaceuticals JAZZ Stock Holding History

Gratry & Company’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$1.02M Sell
6,763
-925
-12% -$136K 1.41% 32
2017
Q4 		$1.03M Sell
7,688
-5,840
-43% -$810K 1.25% 31
2017
Q3 		$1.98M Sell
13,528
-3,512
-21% -$531K 2.42% 15
2017
Q2 		$2.65M Buy
17,040
+9,350
+122% +$1.43M 3.26% 3
2017
Q1 		$1.12M Buy
+7,690
New +$1M 1.37% 30
2016
Q1 		– Sell
-18,534
Closed -$2.6M – 81
2015
Q4 		$2.6M Sell
18,534
-898
-5% -$124K 1.7% 26
2015
Q3 		$2.58M Sell
19,432
-15,011
-44% -$2.58M 1.58% 28
2015
Q2 		$6.06M Sell
34,443
-4,129
-11% -$742K 3.17% 13
2015
Q1 		$6.67M Sell
38,572
-60,701
-61% -$10.4M 3.6% 5
2014
Q4 		$12.6M Buy
99,273
+56,430
+132% +$9.37M 4.12% 1
2014
Q3 		$6.88M Sell
42,843
-9,135
-18% -$1.4M 3.6% 5
2014
Q2 		$7.64M Sell
51,978
-2,242
-4% -$311K 3.01% 15
2014
Q1 		$7.52M Sell
54,220
-45,053
-45% -$6.78M 2.71% 18
2013
Q4 		$12.6M Sell
99,273
-23,845
-19% -$2.47M 4.12% 1
2013
Q3 		$11.3M Buy
123,118
+1,838
+2% +$148K 3.99% 2
2013
Q2 		$8.34M Buy
+121,280
New +$7.41M 3.24% 4

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Gratry & Company's JAZZ Position: Q1 2018 in Review

Gratry & Company reduced its Jazz Pharmaceuticals (JAZZ) stake by 12% in Q1 2018, selling an estimated $136K and leaving 6,763 shares worth $1.02M. The position accounts for 1.41% of the portfolio, ranked #32.

Gratry & Company first reported a position in JAZZ in Q2 2013 and has held it in 16 quarters since. The position peaked at $12.6M in Q4 2014. 323 funds tracked by Wall St. Rank hold JAZZ as of Q1 2018.

  • Gratry & Company held 6,763 shares of Jazz Pharmaceuticals worth $1.02M as of Q1 2018.
  • Gratry & Company sold 925 Jazz Pharmaceuticals shares in Q1 2018, an estimated $136K.
  • Jazz Pharmaceuticals made up 1.41% of Gratry & Company's portfolio in Q1 2018, its #32 holding.
  • Gratry & Company first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
  • Gratry & Company's Jazz Pharmaceuticals position peaked at $12.6M in Q4 2014.
  • 323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2018.

Based on Gratry & Company's 13F filing for Q1 2018, filed 23 Apr 2018.